Skip to main content
OpenTrials
Completed

NCT Number: NCT00960206

ABC/Trident® Ceramic Post Approval Study

The purpose of the Post Approval Study of the ABC and Trident® systems is to continue to demonstrate the safety and efficacy of the alumina-on-alumina bearing surfaces combined with the appropriate shell in a cementless application.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Orthopaedic Surgery Associates, Boca Raton, Florida, United States

Loading trial locations.

About this study

The ABC/ Trident® study was initiated in 1996 as an FDA IDE pre-market study in the United States for alumina bearing THR. PreMarket Approval (PMA)application was approved in February 3,2003. The Post Approval Study (PAS) involved six surgeon investigators from the original IDE study. Subjects who consented to participate in the Post Approval Study continued to be followed to collect limited patient reported data regarding status of the hip.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The individual has signed a Patient Informed Consent (PIC), specific to this study, and approved by the Institutional Review Board (IRB).
  • The individual is between the ages of 21 and 75 years.
  • The individual is not classified as morbidly obese.
  • The individual clinically qualifies for total hip arthroplastic surgery based on physical examination and medical history.
  • The individual is diagnosed with a primary diagnosis of Non-Inflammatory Degenerative Joint Disease (osteoarthritis, traumatic arthritis, avascular necrosis, slipped capital epiphysis, pelvic fracture, femoral fracture, failed fracture fixation or diastrophic variant).
  • The individual does not have an active infection within the affected hip joint.
  • The individual has not had a previous total hip replacement or hip fusion to the affected hip joint.
  • The individual is physically and mentally willing and able to comply with postoperative scheduled clinical and radiographic evaluations and rehabilitation (i.e., not currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, presence of alcohol or substance abuse).
  • The individual does not have a neuromuscular or neurosensory deficiency that limits the ability to evaluate the safety and effectiveness of the device.
  • The individual does not have a diagnosed systemic disease that would affect the subject's welfare or overall outcome of the study (i.e., moderate to severe osteoporosis, Paget's disease, renal osteodystrophy), is not immunologically suppressed, nor receiving steroids in excess of physiologic dose requirements.
  • The individual is skeletally mature.
  • The individual is not pregnant.
  • The individual is not a prisoner.
  • The individual has no plans to relocate to another geographic area before the completion of the study.

Treatment and study plan

Trident® Ceramic Insert/Trident® AD HA Acetabular Shell

Device

Trident® Ceramic Insert/Trident® AD HA Acetabular Shell

Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell

Device

Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell

OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell

Device

OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell

Primary outcomes

  1. Component Revision and Complications

    Time frame: 10 years

    The number of hips in which the study device was removed and replaced with a new component/s is listed. Complications (adverse events) are listed in the adverse event section.

Secondary outcomes

  1. Harris Hip Score

    Time frame: 3-5 and 10 Years

    Scores can range from 0 to 100 with 0 being the worst and 100 being the best score. A score of 80-100 is considered good-excellent and a score less than or equal to 79 is considered fair-poor.

    90 - 100 = excellent

    80 - 89 = good

    70 - 79 = fair

    0 - 69 = poor

  2. Radiographic Evaluation

    Time frame: 3-5 and 10 years

    Failure is defined as progressive femoral radiolucency (RLL) > or = 2mm around entire stem, progressive subsidence > or = 5mm, progressive acetabular radiolucency (RLL) > or = 2 mm around entire cup, or cup migration > or = 3mm.

  3. Hip Follow-Up Questionnaire

    Time frame: 6-10 years

    A three question follow-up questionnaire was administered annually asking whether the participant is satisfied with the study total hip replacement(THR) (noted as "satisfied" below); whether they have any study hip pain (noted as "no pain" below); and whether they have had any surgery on the study hip during the previous year noted as "no surgery" below).

Sponsors and collaborators

Lead sponsor

Stryker Orthopaedics

Industry

Registry information

Official study title

Post-Approval Study of the ABC and Trident® Systems

Important dates

Study start
2003
Primary completion
2010
Study completion
2010
First posted
Aug 17, 2009
Registry last updated
Feb 3, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.